Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRECOS: Safety of CHF5993 pMDI HFA-152a in Asthma
NCT06264674Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in asthma, sponsored by Chiesi Farmaceutici S.p.A.. Started Nov 2023; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06264674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06264674.